Global Pneumonia Diagnostic Market Overview:
Pneumonia is an infectious disease caused by various mediators like bacteria, virus or fungal infections in the lungs. In this disease, there is inflammation of lungs due to the filling of alveoli sacs with fluid (alveoli sacs are the basic and functional unit of lungs). The diagnosis of pneumonia depends on the type of pneumonia occurred and depending on severity. The diagnostic test done mainly by using different technologies. Diagnostic methods are an essential part of the treatment as the direction of treatment is decided by the diagnostic results. Pneumonia is one of the major infectious diseases responsible for significant Deaths and mortality throughout the world. Some of the key players profiled in the study are Abbott Laboratories (United States), Enzo Biochem (United States), Beckman Coulter/Danaher (United States), Becton Dickinson (United States), BioMerieux (France), Bio-Rad (United States), Cepheid (United States), Diamedix (United States), DiaSorin (Italy) and Eiken Chemical (Japan).
On the basis of geography, the market of Pneumonia Diagnostic has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Pneumonia, the sub-segment i.e. Bacterial pneumonia will boost the Pneumonia Diagnostic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Enzyme-Linked Immunosorbent Assay (ELISA) will boost the Pneumonia Diagnostic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Analyzers will boost the Pneumonia Diagnostic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment , the sub-segment i.e. Point-Of-Care (POC) Testing will boost the Pneumonia Diagnostic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing No Of Patients Related to Pneumonia
- Growing No Of Cases In Under-Developed Countries
- Method of Chest Radiography And High-Resolution Computed Tomography(HRCT) are Highly Recommended
- Low Accuracy Of Tests
- Ignored Silent Pneumonia (Walking Pneumonia) During Test
- Different Organisations Taking Initiative To Prevent Pneumonia
- WHO Initiated Global Action Plan For The Prevention And Control Of Pneumonia (GAPP)
- Differentiating Viruses Is Becoming Difficult Due To New Emerging Viruses
- Changing in Lifestyle Causing Viral
Major Market Developments:
In October 2019 Siemens Healthineer AG completed the acquisition 100% of Corindus vascular robotics. Prior to the closing of the acquisition, Corindus held a shareholders’ meeting on October 25, 2019, at which 87.5 percent of their stockholders approved the acquisition. The relevant governmental authorities previously granted the approvals required to complete the acquisition.
In November 2018 BioMerieux announced that food and drug administration clearance BIOFIRE FILMARRAY Pneumonia Panel and the CE mark of the Biofire Filmarray Pnuemonial panel plus. The BIOFIRE FILMARRAY Pneumonia Panels aid in the diagnosis of lower respiratory tract infections.
FDA regulates devices, including in vitro diagnostic devices (IVDs), by classifying devices based on the degree of regulation necessary to provide a reasonable assurance of their safety and effectiveness.
The changing lifestyle, as well as sudden changes in climates, is the reason for spreading infectious diseases which may spread pneumonia. Effective diagnostic kits for such infectious diseases are important for deciding the direction for treatment and speedy recovery. The companies, therefore, are relying more on technological benefits and accurate results in their product. Also they keeping the option of merger and acquisition to earn more profit and to catch the market and lead the market for a long period.
Manufacturers, Distributors/Suppliers/retailers, Wholesalers, Pathology Labs, Hospital & Diagnostic center, Academic Centre, Research Organization and Government organization
Major Objectives Focused through this Study
To define, describe, and forecast the Global Pneumonia Diagnostic market on the basis of product [Streptococcus-based, Legionella-based, Chlamydophila-based, Viral Pneumonia-based and Mycoplasma Pneumonia-based] , application [Hospitals, Commercial/Private Labs, Physician Offices and Public Health Labs], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Pneumonia Diagnostic market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Pneumonia Diagnostic industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Elitech Group (France), Enzo Biochem (United States), Fujirebio (Japan), Grifols (Spain), GlaxoSmithKline (United Kingdom), Hologic (United States), Leica Biosystems (Germany), Lonza (Switzerland), Siemens Healthineers (Germany), Takara Bio (Japan) and Thermo Fisher (United States).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Pneumonia Diagnostic market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.